General discussion, page-17216

Hi ,@sapporo

In relation to your query on the CanQuite pipeline

Minutes from the Sydney meeting

"Gum

1/ CanQuite N 5.2bn market

2/ CanQuite O 64bn market

3/ Rennecan Dermatology Massive market

4/ 6 EDA/EMA underway

5/ Pre IND by xmas

6/Product design underway"
and
7/ "Hiring Head of Corporate Development officer tooversee and concentrate on quick commercialisation of each assets"

Points 4-5 will be key milestones. Point 6 is very muchunderway and shows the confidence by the board. Trials should be conducted in amuch quicker timeframe for CanQuite than IHL other pathways due to the natureof application and administration. The next 12 months will be interesting asthe TAM is huge, especially in the US and Europe high opioid addiction.Addiction to antidepressants is exploding. Interesting to see if this is targeted in the future.
The Dark horse here is the Dermatology market. This is why theboard included Renecan.
As for the acquisition my view was a no brainer.

GL @sapporo.